![]() Objective To estimate the association between receipt of 3 doses of Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273 vaccine and symptomatic SARS-CoV-2 infection, stratified by variant (Omicron and Delta).ĭesign, Setting, and Participants A test-negative case-control analysis among adults 18 years or older with COVID-like illness tested December 10, 2021, through January 1, 2022, by a national pharmacy-based testing program (4666 COVID-19 testing sites across 49 US states).Įxposures Three doses of mRNA COVID-19 vaccine (third dose ≥14 days before test and ≥6 months after second dose) vs unvaccinated and vs 2 doses 6 months or more before test (ie, eligible for a booster dose). Importance Assessing COVID-19 vaccine performance against the rapidly spreading SARS-CoV-2 Omicron variant is critical to inform public health guidance. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.Q < .001 for all comparisons, except for comparing 3 doses vs unvaccinated for N gene for Omicron and for comparing 2 doses vs unvaccinated for the N and ORF1ab genes for Omicron and the S gene for Delta (eTable 2 in the Supplement). Significance testing was performed with a 2-sided Mann-Whitney U test and false-discovery rate–corrected for multiple comparisons. Cycle threshold (Ct) values were compared between 3 doses and unvaccinated, 3 doses and 2 doses, and 2 doses and unvaccinated. Two doses (tested ≥6 months after dose 2) of mRNA vaccine (Omicron n = 7245 Delta n = 4570 total n = 11 815) included vaccination histories BNT162b2/BNT162b2/no third dose, mRNA-1273/mRNA-1273/no third dose, mRNA-1273/BNT162b2/no third dose, and BNT162b2/mRNA-1273/no third dose. Unvaccinated (Omicron n = 3412 Delta n = 5044 total n = 8456) were individuals who received zero vaccine doses. ![]() Data beyond the ends of the whiskers are plotted individually. The whiskers extend to the largest and smallest values up to 1.5 times the interquartile range from the 75th and 25th percentiles, respectively. This included 2857 tests also included in the internal validation of S-gene target failure as a marker for the Omicron variant.įor each plot, from top to bottom, lines in the box represent the 75th percentile, median, and 25th percentile. GThese 52 978 samples were used for the main case-control analysis that compared vaccination status between Omicron and Delta cases and SARS-CoV-2–negative controls. This included 2048 tests also included in the internal validation of S-gene target failure as a marker for the Omicron variant.ĮFor vaccine products, individuals could select from 4 options: Johnson & Johnson/Janssen, Pfizer-BioNTech, Moderna, and “other.”įPersons were considered eligible for a booster if they reported 2 doses, with a testing date 6 months or more after the second dose, or if they reported 3 doses, with the third dose 6 months or more after the second dose. ![]() Vaccination data were considered incomplete if the number of doses reported did not match the products and dates reported.ĭThese 17 177 samples were used for the main case-control analysis that compared vaccination status between Omicron and Delta cases and SARS-CoV-2–negative controls. This included 4905 tests also included in the main case-control analysis.ĬDuring online registration for SARS-CoV-2 testing, individuals self-reported their COVID-19 vaccination status, including the number of doses (up to 4), product, and month and year of receipt for each dose. EUA indicates Emergency Use Authorization.ĪNine tests were removed because of reported ages older than 100 years.īOf all tests with positive results, 17 620 were randomly selected for whole-genome sequencing and used to perform internal validation of S-gene target failure as a marker for the Omicron variant (eTable 1 in the Supplement). Nucleic acid amplification tests (NAATs) were from the Increasing Community Access to Testing platform.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |